^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:Xpovio (selinexor) (XPO1 inhibitor) +
    Darzalex (daratumumab) (CD38 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/12/2021
    Excerpt:
    Therapy for previously treated Multiple Myeloma…Other recommended regimens…selinexor/daratumumab/dexamethasone
    Secondary therapy:
    dexamethasone